ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2018
Warning of an increased risk of vertebral fracture after stopping denosumab.
Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Approach to osteoporosis diagnosis and fracture risk management in primary care.Canadian family physician Medecin de famille canadien · 2026Review
- Longitudinal osteoporosis therapy: treat-to-target and sequential strategies-a narrative review.Therapeutic advances in musculoskeletal disease · 2026Review
- Follow-on osteoporosis therapy after denosumab discontinuation among Medicare beneficiaries.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Trends in Osteoporosis Drug Therapy Receipt Among Commercial and Medicare Advantage Enrollees in the United States, 2011-2022.The Journal of clinical endocrinology and metabolism · 2025Article
- Real-world differences in denosumab persistence, reinitiation, and switching among cohorts of older adults in Canada and the United States.JBMR plus · 2025Article
- First Ecuadorian statement consensus for the evaluation and treatment of osteoporosis.Archives of osteoporosis · 2023Article
- Multiple Spontaneous Vertebral Fractures in a Younger Post-menopausal Woman Upon Stopping Denosumab Therapy.JCEM case reports · 2023Article
- Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.Journal of general internal medicine · 2022Article
- Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea.Endocrinology and metabolism (Seoul, Korea) · 2022Observational
- The current situation in the approach to osteoporosis in older adults in Turkey: areas in need of improvement with a model for other populations.Archives of osteoporosis · 2021Review
- Atypical femur fractures: current understanding and approach to management.Therapeutic advances in musculoskeletal disease · 2020Review
- Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction.Critical reviews in oncology/hematology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.